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Abstract 
Drug misuse causes significant health consequences, morbidity, and mortality. The devastating 
statistics on the opioid epidemic emphasizes the detrimental consequences illegal substances 
have on society. Safe Injection Sites (SIS) allow injection drug users (IDUs) to use drugs in a 
hygienic and low risk environment. Though research supports their efficacy, there is a lack of 
support among the public when assessed anecdotally. Currently, there is no existing empirical 
literature on the public opinion of SIS within the United States. The current study sought to 
bridge this gap by exploring community perceptions of SIS in New York, an area heavily 
affected by the opioid crisis. This study provides evidence that the overall perception of SIS is 
largely undecided. Using hierarchical linear regression, it was found that participants who were 
employed had less favorable views of SIS, participants who are more liberal were more likely to 
support SIS, those with negative attitudes and beliefs towards drugs and drug users reported 
lower support for SIS and those who had familiarity with opioid drugs reported lower 
supportiveness for SIS. Implications for research and policy are discussed. 
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Introduction to Opioid Use 
Opioid addiction rates have significantly increased in the United States in the past 17 
years, resulting in alarming rates of opioid-related overdoses (Centers for Disease Control and 
Prevention [CDC], 2017). In addition to increased overdoses, the opioid epidemic, more broadly, 
has significantly compromised the social and economic welfare and public health of our 
communities. This public health crisis has risen to the national spotlight in more recent years, 
drawing attention to the need for short- and long-term harm reduction policies and practices that 
may mitigate the severity of this epidemic. This review provides a comprehensive understanding 
of opioid use, contributing factors to opioid related deaths, and an overview of Safe Injection 
Sites (SIS), an intervention designed to decrease overdose death. This study sought to address the 
scarcity of literature on community perceptions of SIS among a United States population.  
Opioid Use and Dependency 
Opioids are a category of substances, both legal and illegal, that interact with opioid 
receptors in the brain and body (National Institute on Drug Abuse [NIDA], 2018). Opioids 
include heroin, synthetic opioids (e.g., methadone, tramadol and fentanyl), and legal pain 
relievers (e.g., oxycodone, hydrocodone). Among these, heroin is currently the most commonly 
abused opioid (Praveen, Law, O’Shea, & Melichar, 2011). Opioids reduce the awareness of pain 
and cause euphoria during use. While euphoria is the primary motivation of users, opioid use 
also causes respiratory depression, mental confusion, drowsiness, constipation, and nausea 
(Substance Abuse Mental Health Services Administration [SAMHSA], 2015).  
Repeated use of opioids increases an individual’s tolerance (i.e., the need for more of the 
drug to achieve the desired effect) and dependence (i.e., condition where higher reliance is 
required to maintain drug effectiveness) on the drug, which in turn increases his or her risk for a 
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substance use disorder (Wise & Koob, 2014). Addiction theorists note that substance use 
disorders become compulsive when ongoing intake becomes required (Wise & Koob, 2014). The 
Diagnostic and Statistical Manual of Mental Disorders (DSM), 5th Edition, requires individuals 
to meet three or more of the following criteria to be diagnosed with an opioid use disorder: (1) 
have a strong desire to use opioids, (2) exhibit evidence of tolerance, (3) show difficulties 
controlling behavior at onset, levels of use, and termination, (4) experience withdrawal when not 
using the substance, (5) demonstrate behavior that is consistent with a substance use disorder, 
and (6) neglect pleasures or interests due to opioid use (Praveen et al., 2011). The rise of opioid 
use has significantly increased the rate of opioid overdoses. The risk of opioid-related overdoes 
is directly related to the tolerance that individuals build, as opioid users commonly try to 
intensify their euphoric experiences by increasing their dosage (SAMHSA, 2015), thereby 
inadvertently increasing their risk for detrimental medical complications or death. 
Prevalence 
The devastating statistics regarding opioid use and overdose rates draw attention to the 
detrimental consequences both legal and illegal substances have on society. According to the 
National Institute for Drug Abuse (NIDA), more than 130 Americans die a day from opioid 
overdoses. In 2017, more than 47,000 people died from overdosing on opioids; 494,000 people 
reported using heroin in the past year; 28,000 people died from overdosing on synthetic opioids; 
and 46 people die a day from overdosing on prescribed opioids (U.S. Department of Health and 
Human Services, 2019). 
The Centers for Disease Control and Prevention (CDC) separately analyze four 
categories of opioids, including natural opioid analgesics (e.g., morphine and codeine), 
methadone, synthetic opioid analgesics (e.g., tramadol and fentanyl), and heroin. In an analysis 
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assessing these categories in relation to overdose deaths, synthetic opioids, other than 
methadone, resulted in the highest rates of death. Following this was heroin, then natural opioid 
analgesics, and finally methadone. These findings show that there has been a 17-year increase in 
prescription opioid overdose deaths, and a recent growth in heroin overdoses (CDC, 2017). 
Regardless of the substance itself, opioid involved deaths continue to rise in the United States, 
illustrating the true burden of the crisis within our society. 
Affected Populations 
The greatest increase in opioid use occurred in groups with historically low rates. These 
groups include women, people of higher socioeconomic status, and those who are privately 
insured (CDC, 2017). In 2015, the CDC identified populations who are at greatest risk for having 
a heroin addiction, the most commonly misused opioid. These included Non-Hispanic whites, 
males, those who are 18 to 25 years old, people living in large metropolitan areas, individuals 
who are addicted to cocaine, people addicted to prescription opioid painkillers, and people 
without insurance or enrolled in Medicaid (CDC, 2017). 
The CDC (2017) has also analyzed the top states where opioid overdose deaths have 
significantly increased from 2015 to 2016. West Virginia, Ohio, New Hampshire, Pennsylvania, 
and Kentucky are the five states with the highest rates of drug overdose deaths (CDC, 2017). 
However, there has also been a significant rise in drug-related overdose deaths in other states 
from 2015 to 2016. To recount a few, New York has seen a 32.4% increase, Connecticut has 
experienced a 24% increase, the District of Columbia has seen a 108.6% increase, and New 
Jersey has experienced a 42.3% increase (CDC, 2017). Constituents of these states are 
disproportionately affected when compared to those in other states within the United States. 
As previously mentioned, as an individual increases their consumption of opioids, the 
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tolerance one has developed narrows the gap between the amount required to achieve the 
euphoric effect one desires and the amount of the drug that will cause respiratory depression, and 
ultimately, an overdose (Bird, 2010). Therefore, individuals injecting high quantities of opioids 
are at greater risk for death. Among these types of users, standardized data provide trends in 
drug-related deaths by sex and age group. That is, men are 1.8 times more likely to die from drug 
overdoses than their female counterparts. In addition, older injectors are 2 to 6 times more likely 
than newer users to die from their use (Bird, 2010). Other research has supported these findings. 
In an article analyzing literature on mortality across regions, it was discovered that males had 
higher crude mortality rates (i.e., measure of the number of deaths against the person) and lower 
standardized mortality ratios (i.e., the number of deaths observed in the sample compared to the 
expected number of deaths for a sample of the same age and gender from the general population) 
between different countries. This means that males experienced a higher number of deaths but 
there was no significant difference when comparing between countries (Degenhardt et al., 2011). 
Though the rate of death is higher among males than females, opiate overdose deaths have 
increased 400% among women (SAMHSA, 2015), indicating just as significant of a concern. 
When considering age, the number of youth drug users continues to rise. A study that 
sought to identify prevalence and predictors of heroin-related overdose among young injection 
drug users found six predictors of recent overdose. These six predictors included first injections, 
current cocaine injection and “goofball” injection (heroin and amphetamine use concurrently), 
history of incarceration, having been tested for hepatitis, and witnessing overdoses of others 
(Ochoa et al., 2005). Earlier research has identified differences in the rate of overdose between 
subpopulations of youth. Researchers found that youth who borrow needles and youth who 
identify as LGBTQ were at greater risk for overdosing. Additionally, 48% of the youth 
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participants had experienced an overdose at some point during their use (Ochoa, Hahn, Seal, & 
Moss, 2001). The opioid epidemic does not discriminate, it affects all demographics. 
Nonetheless, there are specific cohorts of the population that are at greater risk for overdose. 
Contributing Factors 
Risk factors may increase vulnerability to addiction, though no single factor contributes 
to the overall existence of the opioid epidemic. As with many other diseases, the greater the 
exposure to risk factors, the greater an individual’s vulnerability. Research has identified several 
biological, environmental, and social risk factors that contribute to this crisis. 
Biological. The medical community did not begin to address addiction until the end of 
the 20th century (Kreek et al., 2012). When addiction began to be explored scientifically, 
scientists found genetic factors that contribute to addiction vulnerability. Studies have shown that 
polymorphisms in several genes, a discontinuous genetic variation which includes genes such as 
opioid receptors and ligands, were identified as correlates of drug addiction (Kreek et al., 2012). 
The most studied polymorphism is a gene known as 118A>G, which produces an amino acid 
substitution. This gene variant has been associated with alcoholism and heroin addiction. 
Carriers of 118G show an elevation in sensitivity to pain (Kreek et al., 2012). Since opioids 
relieve pain, carriers of 118G are at risk for being dependent upon opioids. Furthermore, 118G 
carriers are more sensitive to euphoric effects. This further corresponds with opioid addiction as 
opiates are known to increase euphoria. The 118G gene has shown to be linked specifically with 
opioid dependence, stress responsivity, and treatment responses. This allele is most common 
among Europeans and those of Asian descent and has a lower prevalence among African 
Americans (Levran, Yuferov, & Kreek, 2012). 
Environmental. Research evidence has indicated that environment and life experiences 
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influence drug abuse and the development of addiction. Exposure to a positive environment 
reduces the occurrence of psychiatric disorders and vulnerability to cocaine addiction (Nader et 
al., 2012). Nader and colleagues (2012) examined the correlation between environmental 
enrichment (i.e., positive environmental conditions) and cocaine addiction and found that having 
a loss of environmental enrichment (i.e., chronic exposure to stress) increases risk for drug 
abuse. Accumulating research has shown that environmental enrichment not only reduces the 
risk for cocaine addiction but other drug dependencies as well (Nader et al., 2012). It is 
important to note that typically those living within lower socioeconomic communities have less 
exposure to positive environments. This would infer that drug dependency is higher among this 
population, as loss of environmental enrichment increases vulnerability. However, drug 
dependency among individuals in higher income communities have been steadily increasing 
(CDC, 2017). This would suggest that it is not only physical environmental enrichment but 
perceived enrichment that contributes to dependency (Nader et al., 2012). 
There are an extensive number of familial risk factors that may contribute to substance 
use. Childhood maltreatment, marital status of parents, history of substance use, parent-child 
relationships, socioeconomic status, and level of parental education are among the most common 
and serious risk factors (Whitesell, Bachand, Peel, & Brown, 2013). Childhood maltreatment has 
been linked to a significant increase in risk for adolescents to participate in substance use, with 
29% of children who have been neglected reporting substance misuse. Maltreatment such as 
physical and sexual abuse has also been linked to substance use disorders (Whitesell et al., 
2013). Physical and sexual abuse effect the amygdala, overstimulating this part of the brain, 
thereby resulting in an excess amount of dopamine. An excess in dopamine decreases the brain's 
natural production of the neurotransmitter, which in turn causes an individual to become 
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dependent on a drug to supply the brain with dopamine. High levels of dopamine play a large 
role in the misuse of opiates, ethanol, cocaine, and nicotine (Whitesell et al., 2013). The 
cognitive development of adolescents is a central component when addressing susceptibility to 
substance abuse. Familial factors are a key component to positive cognitive development, and 
when these factors are comprised, individuals are at greater risk for use. 
Social. Social factors also contribute to an increased risk for substance abuse. Some of 
these factors include peer relationships, leisure boredom, and association with gangs. Peer 
pressure is one of the most important risk factors in the development of a substance use disorder 
(Studer et al., 2016). Peer pressure is defined as the pressure to behave a certain way as 
prescribed by our age cohort. There is a positive association between peer pressure and 
misconduct, therefore increasing the risk of deviant behaviors such as drug use. Studer and 
colleagues (2016) analyzed the association between peer pressure and risky substance use. These 
researchers found that, in agreement with previous studies, there is a positive relationship 
between peer pressure and misconduct. They further found that misconduct was significantly 
associated with substance use (Studer et al., 2016). Popularity has also been linked as a risk 
factor to drug dependency. The more an individual believes they are popular among their friend 
group, the more likely they are to conform to peer pressure (Whitesell et al., 2013). 
Deviant peer relationships strongly influence the development of drug dependency. Gang 
affiliation elevates criminal behavior, misconduct, and promotes the cycle of substance use 
(Whitesell et al., 2013). Higher rates of substance use have been reported by individuals who 
identify as belonging to a gang. Moreover, gang affiliation decreases positive parent-child 
relationships which increases negative familial risk factors. Leisure boredom has also been 
identified as a risk factor for increasing substance use. Leisure boredom is the perception of an 
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absence of available leisure experiences that would satisfy needs for arousal (Hendricks, Savahl, 
& Florence, 2015). A study examining whether peer pressure and leisure boredom influenced 
substance use found that leisure boredom as a single factor was not significant in predicting 
substance use; however, in conjunction with leisure boredom, peer pressure and deviant peer 
relationships may precipitate higher prediction of drug dependency (Hendricks et al., 2015). 
Consequences of Opiate Dependency 
Drug dependency causes significant harm to society, the brain, body, and relationships. 
The total economic consequence of misusing opioid prescriptions alone costs the United States 
$78.5 billion a year (CDC, 2017). The costs of healthcare, addiction treatment, criminal justice 
involvement, and lost productivity is a large burden placed on economic welfare. There are also 
tremendous health and social consequences of the opioid epidemic. 
Health. Opioid dependency influences both physical and mental health. Studies have 
suggested that poor health conditions are major contributing factors for an individual to seek 
addiction treatment, giving evidence to the detrimental effects of drug addiction (Mashesha et al., 
2013). Mashesha and colleagues (2013) examined self-reported health status among opioid 
dependent users and found that heroin users who use more frequently reported poorer perceived 
health. However, they also found that almost half of participants perceived themselves as having 
fair or good health (Mashesha et al., 2013). This suggests that being under the influence misleads 
health perception. People suffering from addiction commonly have medical issues such as 
cancer, cardiovascular disease, and cognitive impairments after long-term use (CDC, 2017). 
Continuous misuse of drugs impairs cognitive functioning by adapting memory systems (CDC, 
2017). Additionally, HIV/AIDS, hepatitis B, hepatitis C, tuberculosis, and dental and oral 
hygiene problems are common occurrences among opiate users (Supic, Petrovic, Milicevic, 
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Trajkovic, & Bukumiric, 2013). Often, drug misuse and mental illness coexist, causing greater 
harm as the drug use exacerbates the mental disorder (CDC, 2017). Other research has inferred 
that the relationship between mental illness and substance use disorders is reciprocal rather than 
one leading to another (Fareed, 2014).  
Social. The social-ecological (SE) model focuses on the social components of drug 
addiction (Selbekk, Sagvaag, & Fauske, 2015). It describes how a person’s relationship with his 
or her substance of choice becomes a dominant relationship. This dominant relationship begins 
to unfold at the expense of other social relationships such as intimate or family relationships. 
People rely on the connection in this dominant relationship, and it becomes a person’s source of 
their identity. A cycle of deteriorating connections, disconnections, and intensifications and 
replacements precipitates as the connection of the dominant relationship with drugs becomes 
more prominent (Selbekk et al., 2015). 
Quality of life (QOL) is an overarching concept that has both objective and subjective 
aspects. The objective aspect concerns social, or external, indicators whereas the subjective 
component refers to the personal, or internal, assessment of one's life (De Maeyer, 
Vanderplasschen, & Broekaert, 2009). Researchers examined the concept of quality of life 
among drug users and found that most lacked social inclusion and personal relationships (De 
Maeyer et al., 2009). Drug dependency leads to harm of the individual and their family members. 
Research has shown that family members of individuals with substance abuse disorders have 
been more likely to receive mental health diagnoses themselves (Copello, Templeton, & Powell, 
2010). In addition, family members have higher health-care costs. Though it is difficult to 
understand the extent of effects drug dependency has on family members, there are clear 
negative consequences (Copello et al., 2010). 
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Safe Injection Sites  
 Prevention and interventions can encompass disease prevention, promotion of health, 
detection of illness, treatment, long-term care, rehabilitation, and even harm reduction techniques 
(U.S. Department of Health and Human Services, 2019). The opioid epidemic is so pervasive 
that it requires intervention across a continuum of interventions to promote positive health 
behavior and societal restoration. It is critical to address the opioid epidemic from this lens, 
given the current state of urgency in the United States caused by opioid-related deaths and the 
additional societal costs associated with the rise in use, abuse, and dependency.  
SIS, also known as Safe Injection Facilities (SIFs), is a tertiary level harm reduction 
strategy taken to minimize the impact that overdose deaths will have on the general population. 
SIS allow injection drug users (IDUs) to use pre-obtained drugs in a hygienic and low risk 
environment. SIS are supervised facilities with licensed health care professionals designed to 
reduce public order and health problems that result from illegal injection drug use (Wright & 
Tompkins, 2004). Medical staff do not directly assist in the injection itself, but rather offer 
information on safe injection practices, supply clean injecting equipment, provide referrals to 
health care and addiction treatment services, and monitor clients for signs of overdose (Beletsky, 
Davis, Anderson, & Burris, 2008). Some SIS extend services to other social programs (i.e., 
housing assistance, educational programs), offer medical advice, and provide support to drug 
users who do not inject in order to provide a safe space for all users. Outreach, syringe access 
and disposal, and drug treatment programs are well-regarded for their ability to reduce overdose 
related deaths that are otherwise drastically increasing throughout the world (Beletsky et al., 
2008). 
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History and Locations 
SIS have operated throughout Europe since the 1980’s (Stoever, 2002). However, in most 
discussions, the term “consumption rooms” is used to describe these use-tolerant facilities. Other 
terms synonymous to “consumption rooms” include supervised injection centers, drug 
consumption rooms, health rooms, lane-rooms, fix-rooms, and safe injecting rooms (Stoever, 
2002). Since its first implementation, there have been SIS services developed in 17 Switzerland 
cities, 16 German cities, Danish cities, and throughout Spain.  
The shift from abstinence towards harm-reduction approaches in Switzerland was first 
initiated during the 1980’s (Stoever, 2002). The program was developed in an attempt to control 
the spread of infectious diseases such as HIV/AIDS and hepatitis. Goals for such programs 
included survival of the user, preventing irreversible damage, minimizing deaths and spread of 
diseases, and stabilizing users’ conditions (Stoever, 2002). After implementation of these 
initiatives, needle sharing has decreased significantly, and the prevalence of HIV/AIDS is lower 
than had been feared during the 1980’s. However, Hepatitis C has rapidly increased because the 
sharing of paraphernalia is still commonplace (Stoever, 2002). 
The state of Hamburg officially installed drug consumption rooms in 1994 (Stoever, 
2002). Before then, local drug services tolerated drug use in facilities such as housing projects, 
projects for drug-using prostitutes, and contact houses. Under German opium law, acts of drug 
consumption constituted a criminal offense, making the development of consumption rooms a 
juridical crisis. They were finally legalized by the central government in 2000 through 
“Betaeubungsmittelgesetz,” an amendment to the German federal narcotics law (Stoever, 2002). 
This allowed states to issue their own regulations for operation. Currently, Hamburg, Saarland, 
  
ASSESSING SUPPORT FOR SIS  15 
and North-Rhine Westfalia are the only three states in Germany to issue drug consumption 
regulations.  
Fixelance, a combined ambulance and consumption room, became Denmark’s first 
publicly run consumption room (Ankjærgaard et al., 2015). Fixelance was a beige 1992 Ford 
Transit that was parked in the courtyard of Christiansborg Palace, the Danish parliament. It had 
come from Germany and read “Injecting room and emergency treatment” on the side. The 
vehicle drew public and media attention, aiming to further establish permanent building-based 
consumption rooms. It was parked on Danish parliament on January 26, 2012, and on June 13, 
2012 the Danish government officially approved drug consumption rooms. Thirty-five years 
prior, a contact center in Nørrebro city allowed drug users to inject in their basement and one of 
their toilet rooms. It came to an unexpected end when a social worker disclosed the practice. 
Similar centers also provided underground drug consumption rooms in 24-hour drop in cafes, 
and Copenhagen’s main railway station (Ankjærgaard et al., 2015).  
In 1993, more than half of overdose related deaths throughout Canada were in 
Vancouver, and 90% of these deaths were associated with heroin (Dooling & Rachlis, 2010). 
The opioid epidemic related deaths induced the formation of a task force led by the Provincial 
Chief Coroner, Vincent Cain. In 1994, Chief Coroner Vincent Cain and the task group produced 
the “Cain Report,” which recommended that Vancouver explore SIS (Kerr, Mitra, Kennedy, & 
McNeil, 2017). Although no plans were initiated, SIS grew interest among IDUs. An 
unsanctioned SIS, known as the Back Alley, was run by drug users and operated in 1995 with the 
support of local activists. Efforts to fully establish SIS were bolstered in 2000 and 2001, with a 
number of public events increasing interest (Kerr et al., 2017). In 2003, Vancouver opened North 
America’s first government sanctioned SIS known as Insite (Wood et al., 2007). Insite is funded 
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by a local health authority called Vancouver Coastal Health and is operated between 10:00 am 
and 4:00 am (Wood et al., 2006). Since the newly elected Prime Minister Justin Trudeau in 2015, 
a number of municipalities in Canada have begun developing plans to establish and research SIS 
(Kerr et al., 2017). 
There are currently no SIS operating in the United States. There is also no U.S. law that 
explicitly authorizes or prohibits the implementation of SIS. State legislators potentially have the 
authority to sanction SIS enacting their duty to protect and preserve the welfare of their citizens 
(Beletsky et al., 2008). Local governments and state legislators have the discretion to implement 
SIS and could make SIS legal under state law. However, there are at least 2 sections of the 
federal Controlled Substances Act that could potentially prohibit SIS from being offered. Section 
844 bars the possession of drugs, creating a violation for every IDU client injecting at a safe 
injection facility. Similarly, Section 856 (the Crack House Statute) makes it illegal to knowingly 
open or manage any place using a controlled substance (Beletsky et al., 2008). Though there are 
reasonable legal arguments to bar SIS, some states have already shown interest in developing 
such programs. The Director of Communications at the San Francisco Department of Public 
Health, Rachel Kagan, announced in February 2018 that San Francisco will choose two facilities 
in which to operate SIS (Lieber, 2018). The following week, Philadelphia officials approved a 
similar proposition. More recently, lawmakers and advocates in Albany, NY are making a push 
for SIS in New York State (O’Toole, 2018). These advocates are drawing upon the limited 
research showing favorable outcomes of SIS. 
Outcomes of SIS  
 SIS remains controversial. The United Nations Narcotics Control Board views the centers 
as a violation of international drug conventions (Wright & Tompkins, 2004). However, 
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contemporary research has shown evidence of the benefits SIS provide to both IDUs and the 
surrounding community. Both sides present considerable views, though there is supported 
research for the effectiveness of SIS. 
 Benefits. Evidence of the effectiveness of SIS has primarily come from examining North 
America’s first SIS, Insite. Since the implementation of Insite, overdose death rates have 
decreased by 35% in the surrounding neighborhood (Marshall, Milloy, & Wood, 2011). Research 
examining the patterns of detoxification program initiation among SIS users during periods 
before and after the SIS’s opening found a significant increase in treatment utilization. One study 
found a greater than 30% increase in use of detoxification programs among SIS users (Wood et 
al., 2007). SIS are associated with higher rates of methadone usage, and other treatment services. 
In addition, the increased rate of usage in detoxification program ultimately reduced the 
utilization of the SIS itself (Wood et al., 2007). More research has shown that SIS reduce the rate 
of syringe sharing, which reduces the risk for HIV/AIDS, Hepatitis, and other infectious 
diseases. The SIS was independently associated with reducing syringe sharing when accounting 
for heroin and cocaine injection (Kerr, Tyndall, Li, Montaner, & Wood, 2005). Similarly, there 
has been an overall increase in safe injection practices throughout the community, with no 
significant difference in relapse rates (Kerr et al., 2006). Overall, research conducted on the 
effectiveness of SIS have shown benefits across the board. 
 Studies examining the cost-benefit and cost-effectiveness of SIS are limited but have 
shown potential economic relief. Bayoumi and Zaric (2008) estimated the economic impact of 
Insite on factors such as survival, rates of HIV and hepatitis, and referral to methadone treatment. 
These researchers found that over a span of 10 years, 920 years of life were saved. In addition, 
there was a $14 million net savings based on the assumption of decrease syringe sharing. When 
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factoring health effects and safe injection practices, there was a $20 million overall net savings 
and 1,070 increases in years of life. When considering all three benefits, there was a net savings 
of more than $18 million and 1,175 life years gained (Bayoumi & Zaric, 2008). Subsequent 
research has supported this cost savings analysis. In 2006, the lifetime cost of a new HIV case 
was up to $200,000 in United States’ currency. On average, Insite prevented 35 cases of HIV and 
up to three deaths each year. This ranges from about $2.85 to $8.55 million cost savings and 
$26,000 to $79,000 cost-effectiveness (Andresen & Boyd, 2010). However, more recent research 
has found that there is less economic return when you begin increasing the number of SIS. 
Beyond the third SIS, there is not the same economic return, but it is still cost-effective (Jozaghi, 
Reid, & Andresen, 2013). In sum, establishing SIS has been shown to be cost-effective and 
provide overall economic relief.  
 Controversy. SIS have been long controversial amongst community stakeholders (i.e., 
business owners, residents, legislators, politicians, law enforcement). Arguments against SIS 
include the belief that it will enable drug users to continue using drugs, it will promote the sale of 
drugs and increase crime, and the general morality of allowing drug users to actively inject 
(Strike et al., 2014). Though numerous studies have provided evidence on the effectiveness of 
SIS, researchers have speculated a persistent dissonance between science and public perceptions. 
Ritter and Lancaster (2013) reported a disconnect between research and public opinion. It was 
found that media coverage rarely reported research findings when addressing alcohol and drug 
policies (Ritter & Lancaster, 2013). Media coverage greatly influences public opinion, and the 
nature of coverage may play a role in community stakeholders’ perceptions of SIS. Though 
implementation, regardless of public opinion, may have benefits in increasing supportiveness. A 
study examining changes in public opinion during and after opening between 2003 and 2009 
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found that there was an increase in number of Ontarians who supported Insite after 
implementation (Strike et al., 2014).  
 Public opinion is an important factor to consider in policy making, even though there are 
reported disconnects between science and societal views. Strike and colleagues (2015) identified 
potential reasons for the ambivalence towards SIS among community stakeholders in Canadian 
cities. They found seven underlying reasons for ambivalence: lack of personal knowledge of 
evidence about SIS; concern that SIS goals are too narrow and need to be located within a 
comprehensive response to drug use; uncertainty that the community drug problem is large 
enough; the need to know more about the so-called “right” places to locate SIS to avoid 
damaging communities or businesses; worry that a SIS will renew problems that existed; concern 
that resources for drug use prevention and treatment will be diverted; and concern that SIS 
implementation must include evaluation and community consultation, and explicit commitment 
to discontinue a SIS in the event of adverse outcomes (Strike et al., 2015). When considering the 
opening of a SIS, legislators should make a continuous effort to consult community members.  
The Current Study 
As noted, opioid use causes significant health consequences, morbidity, and mortality. 
The devastating statistics on the opioid crisis draw attention to the need for initiatives directed to 
prevent and minimize the impact of the epidemic. Without continuous efforts, death rates will 
continue to rise. Though research has provided support for the effectiveness of SIS as a harm 
reduction strategy, public opinion still presents controversy. There is no existing literature on the 
public opinion of SIS amongst a United States population. States such as California, New York, 
and Pennsylvania have expressed interest in the implementation of SIS and introduced policies to 
begin that process (Lieber, 2018; O’Toole, 2018), though there is no general knowledge of the 
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perceptions United States community members have regarding their implementation. Moreover, 
there is a considerable lack of research analyzing community variables and their relationship to 
level of SIS supportiveness. It is pivotal to consider public opinion as an important factor in 
policy-making, and to have a general understanding of factors that contribute to opinions on SIS 
implementation. This study sought to fill this gap in the literature. 
The primary purpose of this study was to explore how New York constituents view the 
implementation of a SIS in their community. The research sought to answer two questions: 1) 
What is the perception of SIS among New York constituents? and 2) Are demographics and 
knowledge and attitudes about drug users and drug use related to support of SIS?  
Method 
This non-experimental quantitative survey aimed at assessing the opinion of the public on 
SIS. More specifically, this study sought to determine whether and to what extent a relationship 
exists between individual demographics, knowledge and attitudes about drug users and drug use, 
and supportiveness of SIS.  
Procedure 
 For this study, constituents of New York State were recruited from nine regions of the 
state: Region 1: Long Island (Nassau and Suffolk counties), Region 2: New York City 
(Brooklyn/Kings County, Bronx/Bronx County, Manhattan/New York County, Queens/Queens 
County and Staten Island/Richmond County), Region 3: Lower Hudson Valley (Dutchess, 
Orange, Putnam, Rockland, Sullivan, Ulster and Westchester counties), Region 4: Capital 
Region/Northern Catskills (Albany, Columbia, Delaware, Greene, Montgomery, Otsego, 
Rensselaer, Schenectady and Schoharie counties), Region 5: Eastern Adirondacks/Lake 
Champlain (Clinton, Essex, Franklin, Fulton, Hamilton, Saratoga, Warren and Washington 
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counties), Region 6: Western Adirondacks/Eastern Lake Ontario (Herkimer, Jefferson, Lewis, 
Oneida and St. Lawrence counties), Region 7: Central New York (Broome, Cayuga, Chenango, 
Cortland, Madison, Onondaga, Oswego, Tioga and Tompkins counties), Region 8: Western 
Finger Lakes (Chemung, Genesee, Livingston, Monroe, Ontario, Orleans, Schuyler, Seneca, 
Steuben, Wayne and Yates counties), and Region 9: Western New York (Allegany, Chautauqua, 
Cattaraugus, Erie, Niagara and Wyoming counties) (DEC, n.d.). Sampling did not take place in 
each region; rather, any individual who reported residing in one of these regions during the 
process of data collection was eligible for participation. A priori power analysis was conducted 
using a conventional alpha level of .05 and recommended power of .80 to determine the 
minimum sample size required for the analysis to detect medium-sized effects; a total number of 
114 participants was required. 
Participants were recruited using both in person and online convenience sampling. 
Convenience sampling is a method of sampling where participants are selected based on their 
availability to participate and how easy/convenient it is to access them (Privitera, 2016). Free 
local events and public spaces throughout the Greater Capital Region were utilized for the in-
person recruitment portion of the study. The primary areas for recruitment were free family-
friendly events held by the Troy Business Improvement District (BID), Albany BID, 
Schenectady BID and Saratoga BID between June and August of 2018 (e.g., Troy night out, 
Troy river fest, a taste of Albany, and Schenectady green market).  Because so few participants 
approached at these events agreed to participate, online recruitment was also used. Online 
participants were recruited through a variety of social media sites (e.g., Facebook, Twitter, 
LinkedIn, Craigslist, and Reddit). More specifically, an informational paragraph outlining the 
purpose and intention of the study was posted to a variety of aforementioned social media sites. 
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The paragraph contained a link that brought participants directly to SurveyMonkey which is how 
the online survey was administered. 
Prior to data collection for both in-person and online recruitment, participants were asked 
to sign an informed consent form notifying them about the study’s purpose and that they have the 
option to withdraw their participation at any point during the study with no consequences (See 
Appendix A). For those participants who were recruited online, the informed consent form was 
immediately available upon clicking the link via the social media post. Once informed consent 
was attained, participants were provided with the survey to complete. The survey comprised 
three measures and a brief informational paragraph on SIS. Immediately following the in-person 
survey completion, data were safely secured in an envelope; online participant data was stored 
via SurveyMonkey. Participants who completed the survey had the option of providing their 
email address to be entered in a raffle for a $50 gift card to Amazon (See Appendix F). Both the 
informed consent and email forms were collected separately from the participant data to ensure 
that no identifiable information was able to be linked to individual responses. 
 The American Psychological Association (APA) Ethical Principles of Psychologists and 
Code of Conduct was followed during the process of this study, as were the ethical principles 
outlined in the Belmont Report. In addition, the study was approved by The Sage Colleges 
Institutional Review Board (IRB). 
Participants 
 As noted, study participants were recruited in-person (n = 5) through family friendly 
events and online (n = 116) via a variety of social media sites. All participants were residents of 
New York State at the time of data recruitment. A total of 121 constituents were included in the 
sample.  
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 Participants’ ages ranged from 19 to 70 years, with an average age of 31.65 years (SD = 
11.58). Almost half of the participants resided within the Capital Region/Northern Catskills 
(47.93%); the remaining participants resided in Long Island (4.13%), NYC (6.61%), the Lower 
Hudson Valley (5.79%), the Eastern Adirondacks (8.26%), Central NY (3.31%), Western Finger 
lakes (2.48%), and Western NY (7.44%). No participants resided in the Western Adirondacks. 
The remaining participants (14.05%) failed to report the region they were from. More than half 
of the participants identified as Female (68.60%), and the remaining participants identified as 
either Male (14.88%), Non-Binary (2.48%), or preferred not to say (14.05%). The majority 
(59.50%) of the participants were partnered with the remaining being single (27.27%); 13.22% 
failed to report their relationship status. Most of the participants did not have children (56.20%), 
with 30.58% stating they do; 13.22% neglected to answer this item. Almost all participants 
(72.72%) identified as White, 5.79% identified as Hispanic/Latino, 4.13% as Multiracial, 3.31% 
as Asian/Pacific Islander Adirondacks and the remaining participants (14.05%) failed to report 
their race/ethnicity. Similarly, almost all participants spoke only English (85.95%) in their 
household with 5.78% speaking Spanish, 2.49% as “other” (e.g., ASL [.83%], Bengali [.83%], 
and German [.83%]); 5.78% of the participants failed to report their language. Household income 
varied greatly, as 17.36% reported earning up to $25,999, 17.36% earning between $26,000 and 
$51,999, 16.53% earning between $52,000 and $74,999, 24.79% earning more than $75,000, and 
23.96% declining to say. Religion also varied with 28.93% of participants identifying as 
Christian/Catholic, 23.14% identifying as No Religion, 13.22% identifying as Christian Non-
Catholic, 4.96% identifying as Jewish, 1.65% identifying as Muslim, 2.49% as “other” including 
Buddhism, Pagan, and Secular Spiritual and the remaining participants (25.62%) neglected to 
report this item. For political affiliation, 52.07% of participants identified as Liberal and 33.06% 
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of participants identified as Not Liberal; 14.88% of the participants failed to report their political 
affiliation. Only 5.79% of the participants stated they had a High School Education or less, with 
80.16% stating they had more than a High School Education and the remaining participants 
(14.05%) did not report their educational level. Most of the participants were employed 
(61.98%); 24.79% were unemployed and 13.22% of the participants neglected to report their 
employment status. A complete breakdown of participant demographics is presented in Table 1 
(Appendix G).  
Measures 
 A survey research design was used to solicit demographics, as well as attitudes, beliefs, 
and opinions about drugs and drug use, and supportiveness of SIS using three different 
measurement tools: The Knowledge, Attitudes, and Beliefs (KAB) measure, the SIS measure, 
and a demographics questionnaire. A brief informational paragraph on the definition, procedure, 
and history of SIS was provided to ensure that all survey participants had a general knowledge 
and understanding of SIS. The informational paragraph was provided in between administration 
of the KAB and SIS measures. 
Demographics questionnaire. Thirteen items were developed to collect information on 
participants’ county of residence, gender, age, relationship status, parental status, race and 
ethnicity, income, primary language, religion, political affiliation, education level, and 
employment status. Due to a lack of variability some measures were dichotomized for ease of 
analysis. The demographics questionnaire can be found in Appendix C. 
KAB. The KAB was originally created by the Drug Misuse Research Division of The 
Health Research Board in Dublin, Ireland (Bryan, Moran, Farrell, & O’Brien, 2000), and was 
adapted for use in this study with permission of the Health Research Board. The original survey 
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instrument has 39 items which are broken into three constructs; 1) one item assessing familiarity 
with drugs (i.e., whether participations have heard of various drugs; e.g., cannabis, ecstasy, 
cocaine, heroin, LSD, revelin, and amphetamines, 2) 35 items concerning perceptions, attitudes, 
and beliefs about drugs and drug users, and 3) three items examining whether participants have 
personal knowledge of someone with a drug problem (Bryan et al., 2000). The Drug Misuse 
Research Division demonstrated adequate reliability and validity of the KAB Survey via a 
comparison of results of the KAB Survey to a 'general population survey' (GPS) that was used in 
1999 (Bryan et al., 2000). For the current study, adaptations were made to reflect the language 
and societal formalities of the United States as well as to accurately measure the construct of 
opioid use, in lieu of more general drug use. Prior to administration, a total of 15 items were 
minimally adapted across all KAB items (e.g., questions 1, 6, 7, 12 14, 16, 17, 21, 22, 24, 29, 35, 
37, 38, and 39), and 3 additional items were added (e.g., questions 40, 41, and 42). The full 
adapted version of the KAB can be found in Appendix B. 
Familiarity with drugs.  The first construct of the KAB assessed familiarity with drugs. 
Participants marked off whether they have heard of specific drugs, including methadone, heroin, 
prescription opioids, fentanyl, and tramadol. This variable was scored on a yes (1) or no (0) basis 
for each of these five drugs and responses were summed to produce a scale score; the higher the 
reported score, the more drugs the participants had heard of (M = 4.29, SD = 1.00). 
Perceptions, attitudes and beliefs. The second construct assessed perceptions, attitudes, 
and beliefs on a seven-point Likert response scale ranging from ‘Strongly Disagree’ (1) to 
‘Strongly Agree’ (7). Prior to analysis, 15 ambiguous items from the original scale were dropped 
to improve reliability (e.g., questions 6, 7, 12, 14, 16, 17, 21, 22, 24, 25, 29, 30, 31, 35, and 36). 
The decision of what items to remove was informed by factor analysis. The resulting attitudes 
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and beliefs scale had 20 items. Since the overall direction of the perceptions, attitudes, and 
beliefs statements varied across items, 7 items were reverse coded to reflect accurate scoring. 
The final scale was computed by summing the Likert scale items. Participants who had a higher 
score (highest being 245 and lowest being 35) have more negative attitudes and beliefs towards 
drugs and drug users (M = 124.69; SD = 31.18). Cronbach’s alpha was .90. 
Knowledge of drug users. The final construct of the KAB measure assessed whether 
participants had personal knowledge of someone with a drug problem. Personally knowing 
someone who uses heroin, prescription opioids, fentanyl, methadone, tramadol, or has/had a drug 
problem was also scored on a yes (1) or no (0) basis and all items were summed to produce the 
scale; the higher the score, the more participants know of someone who uses a specific drug or 
has/had a drug problem (M = 2.77, SD = 1.72). 
SIS survey. This measure was developed for this study to assess respondent opinions and 
supportiveness of the use and implementation of SIS. Twenty items were developed to assess 
perceived dangers associated with SIS, perceived benefits associated with SIS, attitudes towards 
policy implementation of SIS, general support for SIS, and perceived locations where SIS 
should/should not be developed. Sample items include “I am in favor of SIS” and “I believe SIS 
will reduce opioid related overdoses.” The items were scored on a five-point rating scale ranging 
from ‘Strongly Agree’ (1) to ‘Strongly Disagree’ (5). Three items were reversed for accurate 
scoring to ensure all items went in the same direction (e.g., questions 11, 14, and 17). Items were 
summed to produce scale scores. Participants who have a higher SIS score (highest being 100 
and lowest being 20; M = 48.84, SD = 18.35) have lower support for SIS. Cronbach’s alpha was 
.96. The full SIS measure can be found in Appendix E.  
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This measure was formulated using the rules for writing survey items as described by 
Privitera (2016) to minimize measurement error. Double-barreled items, which are survey items 
that ask participants for one response on two statements, were avoided and respondents were 
required to respond to one statement at a time. Neutral and unbiased language was used to 
decrease the likelihood of an emotional response and perception of leading terms. To avoid 
problems with participant fatigue, the survey items were minimized and made as brief as 
possible. The SIS was drafted and piloted on 6 individuals to determine comprehension and 
ambiguity of terms. Any items identified as difficult to understand were modified using the 
comments suggested by the pilot group.  
 Brief Informational Paragraph. A one paragraph introduction describing the definition 
of SIS and an overview of the history of SIS was provided to participants in between 
administration of the KAB and SIS measures (see Appendix D). This was developed to ensure 
that all participants had general knowledge of the elements of SIS before completing the SIS 
Opinion Survey. The item was also drafted for the purpose of this study and piloted on 6 
individuals to ascertain difficulty of comprehension. Revisions were made accordingly. 
Data Analysis 
 Data analysis for the study included computing frequencies, descriptive statistics, and 
hierarchical linear regression to statistically assess the relationships between variables. Data 
retrieved were inputted into the IBM SPSS Statistics 25 platform for statistical analysis. All data 
were archived according to the guidelines set forth by the IRB.   
 Frequencies and Descriptive Statistics. Frequency distributions reflecting the number 
of times or how often a score occurs for a given variable were produced. Descriptive statistics, 
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including measures of central tendency and variability were computed for relevant demographic 
variables and scales/subscales.   
 Hierarchical Linear Regression. Hierarchical regression analyses were used to 
determine how participant demographics and knowledge, attitudes and beliefs regarding drug use 
predict overall supportiveness of SIS. Predictors were entered into a series of four blocks. Only 
demographic variables with adequate variability after being dichotomized were considered as 
predictors and were entered into the first three blocks of the hierarchical linear regression. In 
block 1, relationship status was entered as a dichotomous variable (0 = partnered; 1 = single); 
block 1 also included whether or not participants had children (0 = no children; 1 = have 
children). A dichotomous variable for employment (0 = not employed; 1 = employed) was 
entered in the second block. The third block included political affiliation entered as a dichotomy 
(0 = not liberal; 1 = liberal). The fourth block included the three components of the KAB 
measure that were expected to have a relationship with level of SIS supportiveness. Within this 
block, the following were entered as separate variables: (1) familiarity with opioid drugs, (2) 
attitudes and beliefs about opioid drug use and users, and (3) personal knowledge of someone 
who uses opioid drugs. 
Results 
Knowledge, Attitudes and Beliefs Survey 
 Aforementioned, the KAB survey was separated into three sub-scales: (1) familiarity with 
opioid drugs, (2) attitudes and beliefs, and (3) personal knowledge of drug users. Results 
indicated that a majority (52.10%) of participants have heard of the listed drugs before. 
Additionally, only 9.10% of participants did not personally know someone who uses drugs or has 
had a drug problem, albeit 11.60% failed to respond. Lastly, the mean score for the attitudes and 
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beliefs portion of the KAB survey was 124 (SD = 31), meaning that participants overall had 
between a slightly positive and undecided view on drugs and drug users. A slightly positive and 
undecided view on the attitudes and beliefs survey indicates that participants reported either 
disagree moderately (2), disagree slightly (3), or undecided (4) to the overall negative statements 
on the Likert scale. In other words, a mean score of 124 reflects that participants reported in 
between disagree slightly (score of 105) and undecided (score of 140). In context, participants 
either have a somewhat positive attitude towards drugs or are undecided as to how they should 
perceive drugs and drug users. A positive attitude/perception towards drugs and drug users 
would indicate that participants are not afraid of drug users, do not believe all drug addicts are 
dangerous, would not avoid someone who is a drug addict, would not be bothered with having a 
person who is a drug addict living near them, etc.; this suggests a degree of sympathy for drug 
users. An undecided attitude/perception would indicate response ambiguity and that participants 
are unsure of or do not know how to feel/perceive these issues.  
Safe Injection Site Survey 
 Results indicated that the mean score for the SIS survey was 48 (SD = 18) meaning that 
participants had between a slightly agreeable and undecided view of SIS. Since having a higher 
score (highest being 100) on the SIS survey indicates lower support for SIS, the mean score of 48 
conveys that participants reported in between agree (score of 40) and undecided (score of 60) on 
the Likert scale. That is, participants are either undecided about or do not know whether they 
should support SIS or agree with the implementation of SIS.  
Hierarchical Linear Regression 
 As previously noted, a hierarchical linear regression was used to determine how 
participants’ demographics, and knowledge, attitudes and beliefs regarding drug use predict 
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overall supportiveness of SIS. Relationship status, having children, being employed, and political 
affiliation were entered into the first three blocks of the hierarchical linear regression as follows: 
(1) Relationship Status and Having Children, (2) Employment Status, and (3) Political 
Affiliation. The fourth block contained the KAB which was entered as three separate variables: 
(a) Attitudes and Beliefs about opioid drug use, (b) Personal knowledge of someone with an 
opioid drug problem, and (c) Familiarity with opioid drugs. 
 Taken together, relationship status, having children, employment, political affiliation, 
attitudes and beliefs about opioid drug use, personal knowledge of someone with an opioid drug 
problem and knowledge of drugs accounted for 69.5% of the variance in level of supportiveness 
for SIS. In Model 1, neither relationship status, as defined by whether a participant was single or 
partnered, nor having a child were found to be a significant predictor of level of SIS support; 
these variables together only accounted for 8.00% of the variance in SIS supportiveness. In 
Model 2, employment accounted for an additional 6.00% of the variance in SIS support; 
participants who were employed were found to have less support for SIS (β = .485, p < .05). In 
Model 3, participants who reported being more liberal had higher support for SIS; political 
affiliation accounted for an additional 30.00% of the variance in support for SIS (β = -1.126, p < 
.001). When political affiliation was included in Model 3, employment was no longer found to be 
significant, despite its significance in the previous block; this reflects a strong correlation 
between political affiliation and level of SIS supportiveness. The addition of Model 4 added 
26.00% to the variance explained in SIS support. Participants who had overall negative attitudes 
and beliefs towards opioid drugs were found to be less supportive of SIS (β = .582, p < .001), 
and those who had knowledge of opioid drugs were also found to have less support for SIS (β = 
.233, p < .001). Having personal knowledge of someone who uses an opioid drug was not found 
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to be significant in predicting SIS support. Results of the hierarchical regression models are 
presented in Table 2 (Appendix H). 
Discussion 
This study is the first to examine community perceptions of SIS amongst a U.S. 
population. This study sought to answer two questions: 1) what is the perception of SIS among 
New York constituents? and 2) are demographics and knowledge and attitudes about drug use 
related to support of SIS? This study provides evidence that the overall perception of SIS is 
largely undecided and specific demographics, familiarity with opioid drug use, and attitudes and 
beliefs about drugs are related to level of SIS supportiveness. Research has shown that those who 
are at greatest risk for having a heroin addiction include non-Hispanic whites, males, and those 
who are 18 to 25 years old; this study’s participants mainly account for non-Hispanic whites 
(72%), and those who are 18 to 25 years old (38%) (CDC, 2017). Having participants that reflect 
most of the identified affected population for one category of users is useful in gaining insight 
into the consensus of drug perceptions and support of SIS; however, the majority of the 
participants identified as female and do not represent the disproportionate impact of drug usage 
among men.  
 In relation to knowledge, attitudes and beliefs (KAB) of opioid drugs, it was found that a 
majority (52%) of participants have heard of opioid drugs before; only 9.10% did not know 
someone who uses opioid drugs, and participants overall had between a slightly positive and 
undecided view on drugs and drug users. This suggests a degree of sympathy towards drug use 
and drug users since having a positive attitude would mean participants are not afraid of drug 
users, do not believe all drug addicts are dangerous, would not avoid someone who is a drug 
addict, would not be bothered by having a person who is a drug addict living near them, etc. 
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Participants having an undecided attitude/perception indicates response ambiguity and that 
participants are unsure of or do not know how to feel/perceive these issues. Thus, participants 
either have a somewhat positive attitude towards drugs or are undecided as to how they should 
perceive drug use and drug users.  
These findings indicate that although many constituents have knowledge about different 
opioid drugs and have known someone who uses these drugs, they generally do not have a clear 
opinion on opioid issues or their beliefs surrounding the morality and ethics of opioid use.  It is 
not surprising that approximately 90% of participants have known someone who uses an opioid, 
since more than 130 Americans die a day from opioid overdoses (NIDA, 2019). The opioid 
epidemic has risen to a national spotlight in more recent years, drawing attention to the need for 
short- and long-term harm reduction policies and practices, which may give reason to the 
undecided view towards drugs and drug users. Additionally, the national spotlight given towards 
the opioid epidemic may account for 52% of participants’ familiarity with opioid drugs. This 
gives support to research concluding that media coverage greatly influences public opinion 
(Ritter & Lancaster, 2013). 
Analysis of the SIS opinion survey found that participants overall had between a slightly 
agreeable and undecided view of SIS. Again, this means that participants are either undecided on 
supporting SIS or agree with supporting the implementation of SIS. This finding is similar to the 
findings of the KAB survey in that participants generally reported having a somewhat positive or 
undecided perception on drugs and drug users. The hierarchical linear regression used to predict 
overall supportiveness of SIS, found a significant relationship between employment, political 
affiliation, attitudes and beliefs towards drugs and drug users, and knowledge of opioid drugs. It 
was found that participants who were employed had less support for SIS, participants who are 
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more liberal were more likely to support SIS, those with negative attitudes and beliefs towards 
drugs and drug users had lower support for SIS and those who had heard of opioid drugs had 
lower supportiveness for SIS. Participants who were employed may have less support for SIS 
due to the belief that SIS will promote the sale of drugs and increase crime in their location of 
residence. It is not surprising that participants who reported being more liberal were more likely 
to support SIS owning to their political belief that government should take action to reduce 
existing social problems (Khan Academy, n.d.). Similarly, it is not unanticipated that participants 
with negative attitudes and beliefs towards drugs and drug users would have lower support for 
SIS; if you fear drug users in your neighborhood and agree that you would avoid someone who 
uses drugs, it is likely that you would not support the implementation of a SIS in your location of 
residence.  Lastly, the reasoning for why those who have familiarity with opioid drugs have 
lower SIS support may be correlated to having knowledge of the significant adverse effects of 
drugs; if you are familiar with opioid drugs you may also be familiar with the health 
consequences, decreasing your support for a facility that allows injection drug users to inject 
opioids.  
 As previously noted, media coverage greatly influences public opinion; research has 
found a disconnect between research findings and public opinion. It was found that media 
coverage rarely reported research findings when addressing alcohol and drug policies (Ritter & 
Lancaster, 2013). The lack of coverage on research findings when addressing drugs and alcohol 
may account for why participants who have heard of opioid drugs before are less supportive of 
SIS. Similarly, not reporting on the research findings surrounding SIS can explain the overall 
undecided opinion on support for SIS. It is not surprising that political affiliation was a 
significant predictor of level of SIS supportiveness seeing as SIS has long been a controversial 
  
ASSESSING SUPPORT FOR SIS  34 
issue. Public opinion is an important factor to consider in policy making, even though there are 
reported disconnects between science and societal views. Lack of personal knowledge of 
evidence about SIS was found to be one of seven underlying reasons for SIS ambivalence (Strike 
et al., 2015). Since the idea of implementation for SIS is relatively new within the United States, 
lack of knowledge surrounding SIS might give reason to the undecided opinion. Although this 
study did provide participants with an informational paragraph on SIS, the paragraph was brief 
and did not include research analyzing its effectiveness. When considering the opening of a SIS, 
legislators should make a continuous effort to educate and consult community members. 
Additionally, researchers should make a continuous effort to report and articulate SIS findings to 
the general population.  
This research study provides beneficial information to legislators and political 
stakeholders. Though it was found that participants have an undecided opinion towards SIS 
implementation, regardless of public opinion, implementing a SIS may have benefits in 
increasing supportiveness. A study examining changes in public opinion during and after 
opening between 2003 and 2009 found that there was an increase in number of Ontarians who 
supported Insite after implementation (Strike et al., 2014). This increase in supportiveness may 
occur if implemented within the United States as constituents become better informed and are 
able to see results; legislators should take this into consideration when deciding about 
administration of a SIS. It is recommended that future research examine constituent opinions 
before and after implementation if it should occur. Furthermore, state law regarding the legality 
of implementation requires further examination. Currently there is no U.S. law that explicitly 
authorizes or prohibits the implementation of SIS. State legislators potentially have the authority 
to sanction SIS enacting their duty to protect and preserve the welfare of their citizens (Beletsky 
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et al., 2008). While SIS continue to rise in discussion as an opioid epidemic intervention,  
political debate surrounding federal versus state law will become the forefront of implementation 
controversy.  
The United States Health and Human Services (HHS) outlined a 5-point strategy to 
combat the opioid epidemic; (1) better addiction prevention, treatment, and recovery services, (2) 
better data, (3) better pain management, (4) better targeting of overdose reversing drugs, and (5) 
better research (HHS, 2019). This study provides support for SIS within three out of the five 
outlined strategies; better addiction prevention, treatment, and recovery services, better data, and 
better research. The HHS’s strategy for better prevention, treatment and recovery services 
includes funding primarily for addiction treatment and excludes funding for an overdose 
prevention intervention, such as a SIS. In 2017, over $800 million was given in grants to support 
these efforts.  Although research on the cost effectiveness of SIS are limited, it shows promising 
economic relief. When considering survival rates of HIV and hepatitis, and referral to methadone 
treatment, there was a net savings of more than $18 million and 1,175 life years gained 
(Bayoumi & Zaric, 2008). SIS could potentially reduce the amount of money spent towards 
supporting treatment, prevention, and recovery efforts. HHC is supporting rapid response public 
health data and research in “real-time” to analyze what is occurring nationally and at the state 
level. SIS has become controversial in real time throughout the country as a response to reducing 
opioid related deaths. Cities such as San Francisco, Philadelphia, and Albany have made moves 
to implement SIS in their areas using the limited research available (Lieber, 2018; O’Toole, 
2018). This study is the first study assessing community perceptions within the United States and 
provides real time data and research to inform political stakeholders. While our nation continues 
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to research interventions to reduce opioid overdose deaths, SIS ought to be considered as a cost-
effective intervention.  
The current study findings must be considered in light of the study limitations. The 
convenient sampling method of recruitment may restrict the diversity of participant responses; 
this may account for the lack of diversity in participant race and ethnicity. Second, there was a 
considerable amount of missing data within responses of the measures which is more common 
with online surveys. Future research may want to consider shortening the survey length or 
conducting a qualitative analysis examining reasons for or against SIS supportiveness.  In 
addition, the knowledge of drugs portion of the KAB survey does not fully assess participants’ 
understanding of the drugs, just whether they have heard of the drugs before. The extent to which 
the participant has heard of the drug before does not necessarily mean they have an 
understanding of the drug and its effects. Furthermore, the lack of prior literature on the topic 
specific to a U.S. population hinders the investigation of variables that may present as more 
significant predictors than the variables chosen in this study. Future research is needed to expand 
on the variables found significant in this study to further examine their relationships with level of 
SIS supportiveness.  
It is important to note that the original method of recruitment for the study had to be 
revised; the original recruitment method was solely in-person with a written survey instrument. 
After approximately three months of in-person recruitment, it was determined that the amount of 
responses needed to show significance in the study would not be reached. The research design 
was amended to include online recruitment via SurveyMonkey. This proved to be a more 
effective recruitment method and resulted in gaining the recommended 114 responses required 
for analysis; the study was able to retrieve 121 responses.  
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 There is an emerging consensus of literature that gives evidence to the benefits of SIS. 
The success of SIS implementation is dependent not only on the funding available to provide 
services but also on the solidarity of community members. Future research should further assess 
United States public opinion on the implementation of SIS. This may include changes in opinion 
overtime as SIS are implemented and the ways in which key stakeholders can be represented 
when considering changes in policy. Results may be especially relevant to legislators and 
lobbyists in successfully representing their constituents.  
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Appendix A 
 
INFORMED CONSENT FORM 
 
You are being asked to participate in a research project about support for Safe Injection Sites. 
  
This research is being conducted by: Dr. Marisa Beeble (Primary Principle Investigator), Dr. 
Tameka Gillum (Principle Investigator), Dr. Nancy Beshara (Principle Investigator), and 
Kathleen Giarratano (Student Investigator) 
  
What is the purpose of this study? 
The purpose of this study is to gain a better understanding on the perceptions of drug use and 
Safe Injection Sites among adult constituents of the Greater Capital Region. 
 
What does this involve? 
You will first be asked to complete a survey regarding your opinion on drug use, which is 
followed by several demographic questions. You will complete an additional survey assessing 
your overall opinion of Safe Injection Sites. It should take you 10 to 15 minutes to complete this 
study. Your participation in this study is completely voluntary. Should you elect to discontinue 
participation, any information already collected will be discarded. There is no penalty or loss of 
benefit for choosing not to participate. After completion, you have the option of providing 
contact information to be considered to win a $50 Amazon gift card.  
 
How will the information you provide be protected? 
Your identity will be kept confidential to the extent provided by law. This consent form will be 
kept separately from any data you provide, and paper surveys will be kept in a locked file cabinet 
separate from consent documents. Data entered electronically will be password protected. Your 
name will not be used in any report or publication. If provided, your contact information will not 
be used for any purposes other than compensation and will be kept separately from your 
responses.  
 
What are the risks and benefits to participation?  
There are no physical risks to this study. A potential benefit of participating in the study is to be 
able to give your voice on a large political issue that may be used to reform federal and state 
policies. 
  
Who should you contact if you have concerns? 
This project was approved by the Sage Colleges Institutional Review Board. This makes sure 
that the rights of human participants are protected. If you have any complaints, please contact:  
 Dr. Theresa Hand, Associate Provost                                                Phone: 518-244-2069 
The Sage Colleges                                                                              Email: handt@sage.edu 
Troy, New York 12180 
 
Participation is voluntary, I understand that I may at any time during the course of this study 
revoke my consent and withdraw from the study without any penalty. I have been given an 
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opportunity to read and keep a copy of this Agreement and to ask questions concerning the 
study. Any such questions have been answered to my full and complete satisfaction. 
  
I, ________________________________________, having full capacity to consent, do hereby 
volunteer to participate in this research study 
  
Signed: _________________________________________  Date: _________________ 
          Research participant  
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Appendix B 
 
SURVEY ON DRUG-RELATED KNOWLEDGE, ATTITUDES, AND BELIEFS 
 
1. Which of the following drugs have you heard of?  
             Please write X in the box if you have heard of these drugs 
Methadone  
Heroin  
Prescription Opioids (e.g. 
oxycodone, hydrocodone) 
 
Fentanyl  
Tramadol  
 
 
In the following section you will find some statements / questions about drug use and drug users. 
These statements may not necessarily reflect your feelings. There are no right or wrong answers 
to any of these statements, as people have widely different views. Please circle the number that 
best reflects your level of agreement or disagreement with each of the statements.  
 
2. All illegal drugs are equally harmful to your health. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
3. Our society is too tolerant towards drug users. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
4. If you try drugs even once, you are hooked. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
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5. I would see drug addicts more as criminals than victims. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
6. Most young people today would try an opioid.  
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
7. Drug abuse causes more problems in society than alcohol abuse.  
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
8. Treatment should only be given to drug addicts who intend to give up drugs for good. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
9. I would tend to avoid someone who is a drug addict. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
10. I would be nervous of someone who uses illegal drugs. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
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11. Money spent on the prevention of drug use, is money well spent. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
12. The use of opioids should be against the law. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
13. Drug addicts are not given a fair chance to get along in society. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
14. Occasional use of fentanyl is not really dangerous. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
15. People who end up with a drug problem have only themselves to blame. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
16. Most young people today try out opioid prescription pills. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
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17. Drugs are not really a problem to us here in this neighborhood.  
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
18. Treatment should be available to all drug addicts, according to their needs. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
19. Drug addicts really scare me. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
20. Tougher sentences for drug misusers is the answer to the drug problem. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
21. Most people are concerned about the drug problem in the United States. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
22. Occasional use of methadone is not really dangerous. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
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23. Many drug addicts exaggerate their troubles to get sympathy. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
24. It is normal that young people will try drugs at least once. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
25. The drug problem in the United States is out of control. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
26. Medically prescribed heroin substitutes (such as methadone/physeptone) should be 
available to drug addicts. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
27. Almost all drug addicts are dangerous. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
28. Drug education in schools should start at primary level. 
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Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
 
 
29. Drug related crime is a major problem in the United States today. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
30. Occasional use of heroin is not really dangerous. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
31. Reports about the extent of drug usage amongst young people are exaggerated by the 
media. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
32. Society should provide syringes and needles free of charge to drug addicts to avoid the 
spread of HIV/AIDS. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
33. Drug addicts charged with petty offences should be given a choice between treatment and 
prison service.  
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
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1 2 3 4 5 6 7 
 
34. It would bother me to live near a person who is a drug addict. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
35. Regular use of prescription opioids is just as dangerous to your health as regular use of 
heroin. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
36. The availability of illegal drugs poses a great threat to young people nowadays. 
Strongly 
Disagree 
Disagree 
Moderately 
Disagree 
Slightly 
Undecided Agree 
Slightly 
Agree 
Moderately 
Strongly 
Agree 
1 2 3 4 5 6 7 
 
37. I personally know someone who uses heroin. 
Yes No  
0 1 
 
38. I personally know someone who uses prescription opioids.  
Yes No  
0 1 
 
39. I personally know someone who uses fentanyl.  
Yes No  
0 1 
 
40. I personally know someone who uses methadone.  
  
ASSESSING SUPPORT FOR SIS  55 
Yes No  
0 1 
41. I personally know someone who uses tramadol.  
Yes No  
0 1 
 
42. I personally know someone who has/had a drug problem.  
Yes No  
0 1 
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Appendix C 
 
DEMOGRAPHIC SURVEY  
Please answer all of the following questions as they describe you.  
 
1. What is your home zip code? _________  
 
2. Which County of the Capital Region do you reside in?  (circle one) 
☐  Albany 
☐  Columbia  
☐  Greene 
☐  Rensselaer  
☐  Saratoga  
☐  Schenectady  
☐  Warren  
☐  Washington 
☐  Other_________________ 
 
3. What is your gender?  (circle one) 
☐  Female 
☐  Male 
☐  Non-binary 
☐  Transgender  
☐  Prefer not to say 
☐  Prefer to self-describe _________________ 
 
4. What is your age? _________ 
 
5. What is your marital status? 
☐ Married 
☐ Separated 
☐ Divorced 
☐  Widowed 
☐ Single 
 
6. Do you have children? 
☐ Yes 
☐ No 
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7. What is your race/ethnicity? (circle one) 
☐  Asian or Pacific Islander  
☐  Black/African American  
☐  Hispanic/Latino American  
☐  Indian/Native American  
☐  White/Caucasian  
☐  Other _______________________   
 
8. What was your total household income last year?  
☐  $0-25,999  
☐  $26,000-$51,999  
☐  $52,000-74,999  
☐  More than $75,000  
☐  Don’t know/decline to say   
 
9. What languages are spoken in your home? (Mark all that apply)  
☐  English  
☐  Spanish  
☐  Other______________ 
 
10. What Religion do you identify with? (circle one) 
☐  Christian/Catholic 
☐  Christian/Non-Catholic 
☐  Jewish 
☐  Muslim 
☐  Other _____________ 
  
11. What is your political affiliation?  
☐ Very conservative 
☐ Conservative 
☐ Moderate 
☐ Liberal 
☐ Very liberal 
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12. What is the highest degree or level of school you have completed? If currently enrolled, 
highest degree received. 
☐ No schooling completed 
☐ Nursery school to 8th grade 
☐ Some high school, no diploma 
☐ High school graduate, diploma or the equivalent (for example: GED) 
☐ Some college credit, no degree 
☐ Trade/technical/vocational training 
☐ Associate degree 
☐ Bachelor’s degree 
☐ Master’s degree 
☐ Doctorate degree 
 
13. What is your current employment status? 
☐ Employed full time (40 or more hours per week) 
☐ Employed part time (up to 39 hours per week) 
☐ Unemployed and currently looking for work 
☐ Unemployed and not currently looking for work 
☐ Student 
☐ Retired 
☐ Self-employed 
☐ Unable to work 
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Appendix D 
 
INFORMATIONAL SEGMENT 
 
The following description provides a brief overview of the definition, practice, and history of 
Safe Injection Sites. Please read this informational segment and continue to the last portion of the 
study.  
 
 
Supervised Injection Sites provide a legal space for injection drug users to inject pre-obtained 
drugs under professional supervision in a clean environment. At these sites, staff give 
information on safe injection practices, supply clean injecting equipment, and provide referrals to 
health care and addiction treatment services. Safe Injection Sites have operated in Europe since 
the 1980s and in 2003, North America's first site was opened in Vancouver, BC, Canada. Other 
facilities have been established in Australia, but no facility exists in the United States to date. 
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Appendix E 
 
SAFE INJECTION SITE SURVEY 
 
In the following section you will find some statements / questions about safe injection sites. 
There are no right or wrong answers to any of these statements on which people have widely 
different views. Please circle the number which best describes your opinion. 
 
1. I am in favor of Safe Injection Sites. 
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
 
2. Safe Injection Sites are morally wrong.  
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
 
3. I am okay with having a Safe Injection Site in my neighborhood. 
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
 
4. Safe injection sites should not be available to drug users. 
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
 
5. I agree with safe injection sites, but I do not want them in my neighborhood.  
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
 
6. I believe safe injection sites will be a cost-effective initiative.   
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
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7. There should be a Safe Injection Site in the greater Capital Region.  
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
 
8. I would support a Safe Injection Site if one opened in the area.  
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
 
 
9. I believe safe injection sites will reduce opioid related overdoses.  
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
 
10. I would support a person who wants to use a Safe Injection Site.  
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
 
11. Safe Injection Sites will enable drug users to continue abusing drugs.  
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
 
12. Safe Injection Sites will help keep my community clean.  
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
 
13. Safe Injection Sites will reduce crime in my community.  
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
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14. I believe Safe Injection Sites will give the wrong impression to youth.  
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
 
15. Safe Injection Sites will increase entry into addiction treatment.  
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
 
16. Safe Injection Sites will reduce HIV, Hepatitis C, and other transmitted infectious 
diseases by decreasing syringe sharing.  
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
 
17. Safe Injection Sites will increase drug trade.  
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
 
18. Safe Injection Sites will give drug users more access to social-service and health-care 
networks.  
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
 
19. Safe Injection Sites will decrease drug offense arrests.  
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
 
 
20. The United States should allow states discretion about whether or not to implement Safe 
Injection Sites.  
Strongly 
Agree 
Agree Undecided Disagree Strongly 
Disagree 
0 1 2 3 4 
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Appendix F 
 
Thank you for completing this study. If you are interested in being considered to win a $50 
Amazon gift card as compensation for your time, please provide your email address in the 
following space. Your email address will not be used for any purposes other than our gift card 
pool and will be kept separately from your informed consent and responses. Therefore, this form 
will not be connected in any way to the responses you’ve provided.  
 
 
 
 
Email Address: ___________________ 
 
Phone Number: ___________________ 
 
 
I, ________________________________________, having full capacity to consent, do hereby 
allow the researchers to use my contact information in considering me for the Amazon gift card. 
  
Signed: _________________________________________  Date: _________________ 
          Research participant  
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Appendix G 
Participant Demographics  
 
 
 
Table 1   
Participant Demographics  
    
Demographics n % 
Region   
 58 47.93% 
Eastern Adirondacks 10 8.26% 
Western NY 9 7.44% 
NYC 8 6.61% 
Lower Hudson Valley 7 5.79% 
Long Island 5 4.13% 
Central NY 4 3.31% 
Western Finger Lakes 3 2.48% 
Western Adirondacks 0 0% 
Unknown 17 14.05% 
Gender*   
Female 83 68.60% 
Male 18 14.88% 
Non-Binary 3 2.48% 
Prefer Not to Say 17 14.05% 
Age*   
19-25 47 38.84% 
26-32 20 16.53% 
33-39 9 7.44% 
40-46 13 10.74% 
47-53 8 6.61% 
54-60 4 3.31% 
61-67 1 0.83% 
68-74 1 0.83% 
Unknown 18 14.88% 
Relationship Status*   
Not Single 72 59.50% 
Single  33 27.27% 
Unknown 16 13.22% 
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Having Children   
No 68 56.20% 
Yes 37 30.58% 
Unknown 16 13.22% 
Race/Ethnicity   
White 88 72.72% 
Hispanic/Latino 7 5.79% 
Multiracial 5 4.13% 
Asian/Pacific Islander 4 3.31% 
Unknown 17 14.05% 
Household Income   
More than $75,000 30 24.79% 
Between $52,000 and $74,999 20 16.53% 
Between $26,000 and $51,999 21 17.36% 
Less than $25,999 21 17.36% 
Decline to say 29 23.96% 
Household Language   
English 104 85.95% 
Spanish 7 5.78% 
ASL 1 0.83% 
Bengali 1 0.83% 
German 1 0.83% 
Unknown 7 5.78% 
Religion*   
Christian/Catholic 35 28.93% 
No Religion 28 23.14% 
Christian/Non-Catholic 16 13.22% 
Jewish 6 4.96% 
Muslim 2 1.65% 
Buddhism 1 0.83% 
Pagan 1 0.83% 
Secular Spiritual 1 0.83% 
Unknown 31 25.62% 
Political Affiliation*   
Liberal 63 52.07% 
Not Liberal 40 33.06% 
Unknown 18 14.88% 
Education   
More than High School Education 97 80.16% 
High School Education or Less 7 5.79% 
Unknown 17 14.05% 
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Employment*   
Employed 75 61.98% 
Not Employed 30 24.79% 
Unknown 16 13.22% 
* % may not sum to 100 because of rounding error   
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Appendix H 
Regression analysis predicting level of SIS supportiveness 
 
 
 
 
 
 
 
 
Table 2      
Regression analysis predicting level of SIS supportiveness   
Variable 
Model 1    Model 2 Model 3 Model 4 R 
β β β β Change 
Block 1 - Relationship Status 0.287 0.167 -0.106 -0.380 0.081 
                 Having Children 0.331 0.289  0.102  0.075 - 
Block 2 - Employment  0.485  0.213  0.102 0.056 
Block 3 - Political Affiliation   -1.126 -0.435 0.296 
Block 4 - Attitudes and Beliefs     0.582 0.263 
                Knowledge of drug use     0.010 - 
                Familiarity with opioid drugs        0.233 - 
Note: Total R= .695; p < .05. All coefficients are unstandardized; bold indicates that the effect is significant at p < .001 
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